Also trades as: 0IIM.L (LSE) · $vol 0M
ESPR NASDAQ
Esperion Therapeutics, Inc.
1W: +15949.7%
1M: +1.3%
3M: +46.5%
YTD: -14.3%
1Y: +156.4%
3Y: +117.8%
5Y: -84.5%
$3.18
Last traded 2026-07-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (57)
Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
What's Going On With Esperion Therapeutics Stock On Monday?
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results
Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue
Esperion jumps on $1.1 billion ARCHIMED buyout
Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout
12 Health Care Stocks Moving In Friday's Pre-Market Session
Esperion to be Acquired by ARCHIMED
Esperion to be Acquired by ARCHIMED
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Earnings Scheduled For March 10, 2026
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
Insights into Esperion Therapeutics Q4 Earnings
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Quantbot Technologies LP Acquires New Holdings in Esperion Therapeutics, Inc. $ESPR
Here are the major earnings before the open Tuesday
A Peek at Esperion Therapeutics's Future Earnings
Esperion Therapeutics Q4 2025 Earnings Preview
Earnings week ahead: ORCL, ADBE, LI, NIO, HPE, ZIM, KSS, and more
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Esperion Acquires Enbumyst Maker Corstasis
Esperion to acquire Corstasis for $75M upfront payment
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?
Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Moderate Buy” from Analysts
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – Here’s What Happened
Stock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript